chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Height: caller states she used to be 5'1.5 but is shrinking so now she is right under 5 foot; developed a rash about nine days after vaccine/Large Red Hot Rash on left arm; This is a spontaneous report from a contactable consumer (patient). A 77-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection; lot number: EN6205 and expiration date: not reported), via an unspecified route of administration, in Left Arm, on 05Mar2021 at 11:50 (at the age of 77-year-old) as DOSE 1, SINGLE for covid-19 immunization. Medical history included breast cancer 7 years ago. The patient had concomitant medications (unspecified). The patient didn't receive any other vaccines within 4 weeks prior to the COVID -19 vaccine. On 14Mar2021, the patient developed a rash about nine days after vaccine/large red hot rash on left arm, and further stated that she used to be height of 5'1.5 but is shrinking so now she is right under 5 foot on an unspecified date. The patient would like to know if the rash hasn't cleared prior to receiving her second Pfizer Covid vaccine should she receive the vaccine in that same arm. Therapeutic measures were taken as a result of developed a rash about nine days after vaccine/large red hot rash on left arm included Tylenol. The outcome of the event was recovering at time of report while that of the event Height: caller states she used to be 5'1.5 but is shrinking so now she is right under 5 foot was unknown at time of report.  No follow-up attempts are possible. No further information is expected
pt recvd vax & exp a very high fever which last only a few hrs; MD reported 2 pts who were assigned WAES95110413 & 95110414;No further details were provided;
Member has reported was hospitalited for Pulmonary Embolism that happened, COVID-19. States COVID-19 vaccination 02FEB2021, physician ordered to not take therapy until the 2nd COVID-19 vaccination on 23FEB2021. Also, experiencing hands & feet are swollen. Event Ongoing.
Developed chest pain and SOB approx 2 weeks post inoculation with primary SPV.
Shot was given in my upper left arm. They did the same arm for the 2nd dose on 4/27/21 The area hurt after the shot was given for both shots.  That part of my arm is BIG compared to the right arm.  From my shoulder down to the middle of the upper arm  hurts to move.  It's been over 6 months and it REALLY hurts.
10/17 - 6pm - Started feeling soreness & warmth. Noticed bruising at site. Area of soreness, warmth & swelling continued to grow to 5 1/2" x 6". Tried to ice area. 10/21 - Area remains bruised. Not warm to touch. Remains swollen able to palpate edges.
Barking cough, hoarseness, pale, weak, tired, stuffy nose and low-grade temperature.
None Adverse event's reported. This person was only 17 at the time of the vaccine that she got.  We are not sure how this got passed us.
Information has been received from a nurse practitioner concerning a female patient who on unspecified dates was given all three dose of GARDASIL during pregnancy.  Concomitant therapy included MENACTRA.  The nurse practitioner was not informed of the pregnancy until the patient was 6 months pregnant.  On an unspecified date, the patient had a miscarriage.  It was not sure how far into the pregnancy when the miscarriage took place.  Upon internal review, the miscarriage was considered to be an other important medical event (OME).  Additional information has been requested.
Primary immunization series of Pfizer and dose 3 of Moderna; COVID 19; COVID 19; This is a spontaneous report received from a non-contactable reporter(s) (Physician). The reporter is the patient.  A 57-year-old male patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), as dose 3 (booster), single (Batch/Lot number: unknown) and in May2022 as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "vestibular migraine" (unspecified if ongoing); "low back pain" (unspecified if ongoing); "known allergies: PCN" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant), outcome "unknown", described as "Primary immunization series of Pfizer and dose 3 of Moderna"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive; (Jan2023) Negative, notes: antigen testing after 6 days of Paxlovid. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: Paxlovid, treatment start date=16Jan2023, treatment stop date=21Jan2023, Lot number=2692144, Indication=treatment of covid-19. Adverse event: rebound of symptoms. Negative by antigen testing after 6 days of paxlovid.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on the available information in the case, the causal association between the events INTERCHANGE OF VACCINE PRODUCTS, COVID-19, DRUG INEFFECTIVE and the suspect drug BNT162B2 cannot be excluded.
Vaccination adverse reaction; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Vaccination adverse reaction) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Vaccination adverse reaction). At the time of the report, VACCINATION COMPLICATION (Vaccination adverse reaction) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications and event treatment information was not provided by the reporter.
Past lot that had also been expired that was administered to Patients; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Past lot that had also been expired that was administered to Patients) and NO ADVERSE EVENT (No adverse event) in a 60-year-old female patient who received mRNA-1273 (Spikevax) (batch no. O70H21A) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Past lot that had also been expired that was administered to Patients) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Past lot that had also been expired that was administered to Patients) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Past lot that had also been expired that was administered to Patients).    Patient's age was reported as 60 Year 4 Month.  Concomitant product use was not provided by the reporter.  It was reported that also another lot of vaccines lot number 065F21A was also expired and administered to patient and lot number O70H21A this was administered to patient in between 08-Apr-2022 and 15-Dec-2022.  Treatment information was not provided.  NDCID number was reported.
Client presented to off-site COVID19 vaccination clinic (through Health Department) on 1/18/2022 for her first dose of Moderna Vaccine. Patient inadvertently received 1mg of Moderna vaccine instead of 0.5mg. Called client today (01/19/2022). Complains of mild side effects - sore arm (at injection site), headache, and fatigue. No other complaints noted.
Patients right arm is red and warm to the touch. She also states that it feels tight and sore to move.
Menstrual period was delayed by 1 week exactly, which is abnormal for the patient who has very consistent menstrual cycles. Major back pain and cramping was involved and patient treated with OTC pain medication.
3 to 4 weeks after MMR vaccine her lower back broke out in with pus filled vesicles that were painful.  In the following days she developed hives on her arm, neck, torso (front & back).  A pinprick red rash developed on her leg and inside of her elbows.  She went to the Clinic.  He told her it looked like two different causes to her rash.  She did not tell him she had had the MMR vaccine during the visit.  He started her on a week of prednisone.  The client experienced considerable relief with the treatment. She does still have the pinprick rash on her neck and she takes Benadryl before going to bed because the itchiness increases through the night.  Sometimes the Benadryl doesn't work.
Got the 2 shot deal about 2 years ago guess what yep got shingles again/suspected vaccination failure; Shingels; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   The patient's past medical history included shingles.   On an unknown date, the patient received the 2nd dose of Shingles vaccine and the 1st dose of Shingles vaccine. On an unknown date, less than a year after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (Verbatim: Got the 2 shot deal about 2 years ago guess what yep got shingles again/suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: Shingels). The outcome of the vaccination failure was unknown and the outcome of the shingles was not resolved.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine and Shingles vaccine.     It was unknown if the company considered the vaccination failure and shingles to be related to Shingles vaccine and Shingles vaccine.   Additional Information: GSK Receipt Date: 27-JUN-2023 and 28-JUN-2023 This case was reported by a patient via interactive digital media. The patient got the 2 shot deal and I got it again last year, lasted couple of months and was worse than previous time.  Patient stated now I have it again. The follow-up could not be possible as no contact details were available. This case was considered as suspected vaccination failure as details regarding laboratory test and time to onset confirming shingles was unknown at the time of reporting.
The evening of the second shot I developed a very bad headache. I didn't take anything for it as I was advised that taking tylenol or motrin could cause the shot to not be as effective. Anyhow, by the following morning the headache was gone. However later that morning I developed a pulsating whooshing sound in my left ear. It was loud, painful, and annoying. The sound and feeling lasted for about 8 days. After that, it went away and was replaced by a high pitched continuous beep sound that seemed to be in both ears.. That lasted another week or so. Then it was blessedly quiet for a couple of days. Then the sound came back and I have periods of that noise and then periods of the pulsating whooshing sound (though to a lesser degree than the first week of them). As I sit here typing, the whooshing and pulsing is happening in my left ear.   Initially I mentioned this to my PCP on 4/13 and she suggested a course of flonase and attributed it to some fluid build up due to allergies. However, it never seemed to make a difference.   Also, 6 weeks out from the vaccine I developed an SVT for which I am now going to have to have surgery to correct.
-he came to the hospital with a chief complaint of altered mental status.  That happened today while he was having his dialysis at the dialysis center.  This was reported by the staff at the dialysis center.  Patient's daughter was called by the dialysis center staff reporting that the patient was confused.  This was not his baseline.  Due to altered mental status he was sent to the hospital by ambulance for further evaluation and treatment.  According to the patient's daughter who provided me entire history on the phone the patient has these episodes of altered mental status every time he has urinary tract infection.  He has history of multiple urinary tract infection. Tested positive on 8/27/2021. He came to the hospital with a chief complaint of altered mental status. That happened today while he was having his dialysis at the dialysis center. This was reported by the staff at the dialysis center.  Patient's daughter was called by the dialysis center staff reporting that the patient was confused. This was not his baseline. Due to altered mental status he was sent to the hospital by ambulance for further evaluation and treatment. According to the patient's daughter who provided me entire history on the phone the patient has these episodes of altered mental status every time he has urinary tract infection. He has history of multiple urinary tract infection in the past. History taking was extremely limited from the patient due to metabolic encephalopathy. Most of the history was obtained from the previous medical records in the patient's daughter on the phone. Apart from altered mental status no other symptoms were reported.
Female patient of 64 years of age, CAOX3 was in the area of observation begins to report feeling strange when swallowing feeling of inflamed tonsils. Patient kept under observation and then refers to itching of left ear. 25mg of Benadryl P.O. is administered by medical order of Dr. Reports improvement of symptoms within 30 minutes of taking the medication.
Found on floor in bathroom in early AM of 7/17/22. Unresponsive. CPR initiated and 911 called. Taken to hospital, where he passed away.
Systemic: Numbness (specify: facial area, extremities)-Mild, Systemic: Tachycardia-Mild, Systemic: Weakness-Mild, Additional Details: pt reported numbness in hand right after administration. monitored bp and hr after pt reported heart felt like it was racing. measured bp 127/98, hr 66. pt seemed nervous prior to administration
initial onset of on-going upper respiratory infections, swollen glands, sore throat, sinus infections, joint pain, fatigue, general unwell feeling, short term memory problems, mild neutropenia, pneumonia, strep throat, low IgA, mouth sores; on-going: not yet resolved
Patient received first dose of COVID vaccine at 1800 and waited 15 minutes and left on his own accord.  He sat in his car a few more minutes with his wife not feeling as if he was completely well.  He returned to the clinic reporting tightness in his neck and throat area.  His blood pressure was taken 189/99.  He did not have difficulty breathing or any other signs of anaphylaxis but was given 50mg of benadryl as a precaution.  We continued to monitor blood pressure for 30 minutes and did not resolve.  He has a history of high blood pressure but reports that it is controlled by taking Metoprolol and Amlodipine daily.  Physician was consulted and felt it was best to be seen in the ER.  The patient was transported to ER by his wife and seen.
Local board of health nurse administered 0.25 of FLULAVAL QUADRIVALENT vaccine to a 2 year old patient. (Vaccine licensed for 3 and older). She contacted the State Department of Public Health, who let her know that most likely the patient would needed to be contacted and revaccinated. The Local Board of Health nurse stated there were no adverse events noted in the patient. The nurse at the State DPH contacted GSK to ensure that this was indeed the case. A pharmacist at GSK stated that they do not have any data on the 0.25 dose, only on 0.5 dose and that they had recently filed papers to extend the age limit down to 6 months on FLULAVAL, but using a 0.5 dose. The GSK pharmacist confirmed that this patient should revaccinated with the correct flu vaccine for her age. This was communicated to the Local Board of health nurse by the State DPH nurse.
Excessive sorenes, per patient, not able to fully use arm, waiting on patient to visit physician.
Soreness at the site after getting the vaccine; The rash is a contact dermatitis; Itchy rash; This case was reported by a consumer via call center representative and described the occurrence of contact dermatitis in a 53-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included hormone replacement therapy. Concurrent medical conditions included fibromyalgia.   On 24th December 2019, the patient received the 1st dose of Shingrix (intramuscular). In December 2019, less than a week after receiving Shingrix, the patient experienced contact dermatitis and itchy rash. On an unknown date, the patient experienced injection site pain. The patient was treated with steroids nos (Steroids). On an unknown date, the outcome of the contact dermatitis and itchy rash were recovering/resolving and the outcome of the injection site pain was resolved with sequelae.   It was unknown if the reporter considered the contact dermatitis, itchy rash and injection site pain to be related to Shingrix.  Additional details were received as follows: This case was reported by patient herself. The patient received the first dose of Shingrix and had some soreness at the site after getting the vaccine. Within week after vaccination, the patient developed an itchy rash. The patient had been seen a provider about her rash and a biopsy was taken. The patient stated that the rash was a contact dermatitis from either Shingrix or her hormone replacement therapy. The patient did not consent to follow up.      Lab Comments: on an unknown date biopsy was done
>35 days between doses; severe reactions; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (severe reactions) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (>35 days between doses) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Jul-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, the patient experienced VACCINATION COMPLICATION (severe reactions). On 22-Jul-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (>35 days between doses). On 22-Jul-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (>35 days between doses) had resolved. At the time of the report, VACCINATION COMPLICATION (severe reactions) outcome was unknown.            No concomitant medications were not reported. No treatment medications were not provided.   This case was linked to MOD-2021-322725.
Has underlying dementia and often with difficulty eating.  1 week after immunization she developed a stroke with left sided weakness and difficulty swallowing.  Comfort measures instituted.  Not sure if this is related to the vaccine, but thought I should report
Large local reactions, soft-ball sized or larger, at shot site. Local reaction was accompanied by aching/ swelling in shoulder and elbow joints. Most recent 2 reactions were accompanied by chest pain. Symptoms lasted several weeks. No medical prescription sought.
Pt recvd 1st dose of Hep B vax 6FEB91 & that evening pt exp a burning sensation @ site of the inject; On 10FEB91 pt devel chest pain, h/a, SOB, & t104; SMAC, CXR & diathermy were WNL; MD felt pt sx were related to vax;
Breakthrough case admission after 5 vaccines Pfizer 1/16/21 Lot# EL3249;  Pfizer 2/6/21 Lo# EM9810;  Moderna 8/18/21 Lot# 040C21A;  Moderna 4/14/22 Lot# 056M21A; Pfizer  9/23/22 Lot# GH9703
Thursday 3/2/23 started with headache, Friday 3/3/23 started dizziness, Saturday 3/4/24 started with Rash/hives on Face and arms.
I had a raised circle at the injection site the day after the vaccine. It went away and then reappeared 7 days later. A rash is forming around the raised area. The rash is spreading a little more each day.  It is itchy, red and warm.
About 10 hours after my second dose, I began to have muscle pain. The muscle pain is different than body aches that I?ve gotten with a cold. My muscles hurt and my skin is sensitive to the touch. It feels like the pain goes from the skin to the bone. I don?t know how else to describe it other than  feeling like a bad a sinus infection inside of my muscles. I know that?s a weird way to describe it but the pain is kind of indescribable and unique. The pain is worst in my neck and back. My joints also feel inflamed, it?s hard to close my hands into a fist. I spent most of the night freezing cold and shivering (I live without air conditioning).  It has been  about 35 hours since I received the vaccine. Cold and shivering has subsided but I have have the sweats for the past 8 or so hours. A bit of nausea and stomach pain started about 15 hours after the vaccine.
pt recv vax 2JUN95 & 30MAY97 pt devel breakthrough chickenpox;
Flu vaccine injection at pharmacy failed to immunize. Ill with flu 10-26 to present 11-5-2010. I suspect the virus type or the amount of the vaccine was in error.
Shortness of breath (~6 hours post-vaccine), fever (24 hours post-vaccine), chills (~18 hours post-vaccine), joint pain (12 hours post-vaccine), extreme fatigue (~18 hours post-vaccine), shaking hands (~18 hours post vaccine), chest pain (12 hours post-vaccine)
This spontaneous report as received from a pharmacist refers to a newborn female patient of unknown age. On 02-nOV-2012 at 11:03, the patient was vaccinated with RECOMBIVAX HB that had been exposed to temperatures below 32F for 6 hours. During that 6 hour time period, the vaccine was exposed to 28.8F for 1.5 hours. Administration route was not provided. Two lot # were involved and the lot # were reported as: 0294AE, expiry date on 06-SEP-2014; and 0395AE, expiry date on 08-NOV-2014. It was unspecified which lot # the patient was administered. The outcome of event was unknown. It was unspecified if the patient sought medical attention. This is one of several reports received from the same source. Additional information has been requested.